Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN EBITDA Margin
EBITDA as a percentage of revenue.
Elanco Animal Health IncorporatedNYSE: ELAN
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin narrows to 6.6%
EBITDA Margin was 6.6% in Q3 FY2026, down 9.1 pp from a year earlier. On a trailing-twelve-month basis it was 13.2%, down 6.2 pp year over year. Over 3 fiscal years it narrowed by 5.3 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 9 analysts of 29.4% for the fiscal year ending Dec 2026, up from 14.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- 6.6%-13.5 pp QoQ
- Last fiscal yearDec 2025
- 14.3%-19.2 pp YoY
- LTMSep 2026
- 13.2%-6.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.1 pp | +25.9 pp | +35.0 pp |
| 1 year | -19.2 pp | +15.1 pp | +34.3 pp |
| 3 years | -5.3 pp | +12.9 pp | +18.2 pp |
| 5 years | +11.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 14.3%
- Year-over-year change
- -19.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.3% | -19.2pp |
| FY2024 | 2024-12-31 | 33.5% | +38.6pp |
| FY2023 | 2023-12-31 | -5.1% | -24.7pp |
| FY2022 | 2022-12-31 | 19.6% | +11.0pp |
| FY2021 | 2021-12-31 | 8.6% | — |
EBITDA Margin vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's LTM Sep 2026 EBITDA Margin of 13.2% is the 5th highest of the 6 companies compared; the peer median is 21.0%.
- Its year-over-year change of -6.2 pp is the 5th highest of 6, against a peer median of +0.0 pp.
- Over three fiscal years its change of -5.3 pp compares with a peer median of +3.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 42.0% | -1.1 pp | +1.4 pp | |
| LTM Sep 2026 | 34.9% | +0.0 pp | +4.9 pp | |
| LTM Jun 2026 | 21.0% | -18.3 pp | +7.6 pp | |
| LTM Mar 2026 | 15.0% | +4.5 pp | -1.1 pp | |
| LTM Sep 2026 | 13.2% | -6.2 pp | -5.3 pp | |
| LTM Aug 2026 | 11.9% | +111.0 pp | +3.8 pp | |
| Peer median (excluding ELAN) | 21.0% | +0.0 pp | +3.8 pp | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.76B | 4.41B | 4.42B | 4.44B | 4.72B |
| Cost of Revenue | 2.69B | 2.44B | 2.48B | 2.53B | 2.67B |
| Gross Profit | 2.08B | 1.97B | 1.94B | 1.91B | 2.05B |
| Gross Margin | 43.6% | 44.7% | 43.9% | 43.0% | 43.5% |
| Research & Development | 369M | 321M | 327M | 344M | 368M |
| Selling, General & Admin | 1.4B | 1.27B | 1.29B | 1.31B | 1.43B |
| Operating Expenses | 1.77B | 1.59B | 1.61B | 1.66B | 1.8B |
| Depreciation & Amortization | 716M | 682M | 694M | 662M | 680M |
| EBITDA | 409M | 866M | (224M) | 1.49B | 676M |
| EBITDA Margin | 8.6% | 19.6% | -5.1% | 33.5% | 14.3% |
| Operating Income | 304M | 384M | 326M | 251M | 252M |
| Operating Margin | 6.4% | 8.7% | 7.4% | 5.7% | 5.3% |
| Interest Income | 0 | 0 | 0 | 0 | 45M |
| Interest Expense | 264M | 256M | 277M | 339M | 220M |
| Other Income / Expenses | (875M) | (456M) | (1.52B) | 237M | (476M) |
| Income Before Tax | (571M) | (72M) | (1.2B) | 488M | (224M) |
| Pre-Tax Margin | -12.0% | -1.6% | -27.1% | 11.0% | -4.8% |
| Income Tax Expense | (88M) | 6M | 36M | 150M | 8M |
| Net Income | (483M) | (78M) | (1.23B) | 338M | (232M) |
| Net Margin | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| EPS (Basic) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| EPS (Diluted) | (0.97) | (0.15) | (2.50) | 0.68 | (0.47) |
| Weighted Avg Shares | 487.2M | 488.3M | 492.3M | 494M | 496.4M |
| Weighted Avg Shares (Diluted) | 487.2M | 488.3M | 492.3M | 497.3M | 496.4M |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.